Spots Global Cancer Trial Database for Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
Official Title: Retrospective, Multicenter, Observational Study to Evaluate Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in Japanese Patients With HR+/HER2- Advanced Breast Cancer in First Line or Second Line Settings
Study ID: NCT05399329
Conditions
Study Description
Brief Summary: This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting. For the purposes of this study, analyses will be descriptive in nature. No formal hypothesis testing is planned.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nagoya University Hospital, Nagoya, Aichi, Japan
National Hospital Organization Shikoku Cancer Center, Matsuyama-city, Ehime, Japan
Japan Community Health care Organization Kurume General Hospital, Kurume-city, Fukuoka, Japan
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan
Kitasato University Hospital, Sagamihara, Kanagawa, Japan
Tohoku University Hospital, Sendai, Miyagi, Japan
Kaizuka City Hospital, Kaizuka, Osaka, Japan
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan
Osaka University Hospital, Suita-city, Osaka, Japan
Saitama Prefectural Cancer Center, Kita-adachi-gun, Saitama, Japan
Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
Gifu University Hospital, Gifu, , Japan
Hiroshima University Hospital, Hiroshima, , Japan
Tokai University Hospital, Kanagawa, , Japan
Aichi Cancer Center, Nagoya, , Japan
National Hospital Organization Osaka National Hospital, Osaka, , Japan
Shizuoka Prefectural Hospital Organization, Shizuoka, , Japan
Showa University Hospital, Tokyo, , Japan
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
